Results 211 to 220 of about 6,807,044 (341)

Nationwide Analysis of PCI After TAVR From the Netherlands Heart Registration

open access: yesCatheterization and Cardiovascular Interventions, EarlyView.
ABSTRACT Background Percutaneous coronary intervention (PCI) after transcatheter aortic valve replacement (TAVR) has gained interest as concomitant coronary artery disease (CAD) is now often treated conservatively before TAVR, and TAVR is increasingly used in younger patients with longer life expectancies. Therefore, more contemporary data on PCI after
Hugo M. Aarts   +7 more
wiley   +1 more source

Self‐Management Interventions in Young Adults (18–30 Years) With Type 1 Diabetes, Sickle Cell Disease, and Inflammatory Bowel Disease: A Scoping Review

open access: yesChronic Diseases and Translational Medicine, EarlyView.
ABSTRACT Fluctuating chronic conditions (FCC) in young adults aged 18–30 years, such as type 1 diabetes (T1D), sickle cell disease (SCD), and inflammatory bowel disease (IBD), present unique self‐management challenges due to unpredictable symptom patterns that disrupt daily life.
Reham Almabadi   +3 more
wiley   +1 more source

Results of the ACCOuNT Trial: A Multi‐Institutional Prospective Pharmacogenomics Implementation Trial for African American Inpatients

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
Pharmacogenomics implementation efforts have increased over the last decade, but no published prospective pharmacogenomics trials have formally evaluated utility in underrepresented populations. We present final results from the ACCOuNT trial, a multi‐institutional prospective study [NCT03225820] in which African American inpatients were genotyped and ...
Zhong Huang   +17 more
wiley   +1 more source

Impact of barcode medication administration on patient safety in UK hospital settings: protocol for a mixed-methods realist evaluation. [PDF]

open access: yesBMJ Open
Mahmoud A   +9 more
europepmc   +1 more source

Safety, Pharmacokinetics, and Pharmacodynamics of Osivelotor for Sickle Cell Disease: First‐in‐Human Studies in Healthy Participants and Patients

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
The investigational agent osivelotor, a small molecule hemoglobin (Hb) modifier in development for the treatment of sickle cell disease (SCD), acts by increasing Hb‐oxygen affinity and inhibiting the polymerization of sickle Hb. We report safety, pharmacokinetic (PK), and pharmacodynamic (PD) data from the first two phase 1 clinical trials of ...
Eleanor A. Lisbon   +15 more
wiley   +1 more source

Home - About - Disclaimer - Privacy